



CCR4 is a prognostic biomarker and correlated with immune infiltrates in head and neck squamous cell carcinoma

Yijian Zhang^{1#}, Kai Chen^{2#}, Li Li^{3#}, Weidong Mao⁴, Dong Shen⁴, Ninghua Yao^{5^}, Lei Zhang¹

¹Department of Otolaryngology-Head and Neck Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China; ²Department of Radiotherapy, First People's Hospital of Yancheng, Yancheng, China; ³Department of Oncology, Huaian Hospital, Huai'an, China; ⁴Department of Oncology, Jiangyin People's Hospital, Wuxi, China; ⁵Department of Oncology, Affiliated Hospital of Nantong University, Nantong, China

Contributions: (I) Conception and design: Y Zhang, L Zhang; (II) Administrative support: L Zhang, W Mao; (III) Provision of study materials or patients: K Chen; (IV) Collection and assembly of data: L Li; (V) Data analysis and interpretation: Y Zhang, D Shen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Lei Zhang. Department of Otolaryngology-Head and Neck Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China. Email: wxzhl@139.com.

Background: Increased evidence has indicated that the tumour microenvironment plays an essential role in the development, treatment and prognosis of head and neck squamous cell carcinoma (HNSC). Recent studies have indicated CC chemokine receptor 4 (CCR4) plays an essential role in tumor invasion and other adverse biological behavior. This study used data from the Cancer Genome Atlas (TCGA) database to explore the role of *CCR4* in HNSC and its clinical significance.

Methods: The gene expression and clinical data of HNSC patients in the TCGA database were extracted. Gene Expression Profiling Interactive Analysis (GEPIA) was used to analyze the expression of *CCR4* in tumor and non-tumor tissue. Kaplan-Meier survival analysis was used to analyze the relationship between *CCR4* expression and overall survival rate (OS), disease-specific survival (DSS), and progression-free interval (PFI) in HNSC. A logistic regression model was used to analyze the relationships between various clinical factors and *CCR4* expression. Gene Set Enrichment Analysis (GSEA) was used to explore the potential role of *CCR4* in HNSC. Additionally, we explored the relationship between *CCR4* and immune infiltration.

Results: The expression of *CCR4* in HNSC was not significantly different from that in normal tissue. The expression level of *CCR4* in wild-type TP53 was higher than that in mutant TP53. Cox regression analysis showed the expression level of *CCR4* was related to the patient's tumor grade and Tumor-Node-Metastasis (TNM) stage. *CCR4* expression level is an independent prognostic factor. *CCR4* is positively correlated with immune infiltration and immune checkpoints expression levels. The results of GSEA revealed that the high *CCR4* expression group genes were enriched in allograft rejection, inflammatory response, IL-6/JAK/STAT3 signaling, interferon gamma response, and KRAS signaling up. Low *CCR4* expression group genes were enriched in oxidative phosphorylation, MYC targets v1, DNA repair, reactive oxygen species pathway, and P53 pathway. Further, our study indicated *CCR4* can also predict the prognosis of radiotherapy patients.

Conclusions: Our study found that *CCR4* was a prognostic marker related to HNSC immune infiltration, and patients with high expression of *CCR4* had a better prognosis.

Keywords: CC chemokine receptor 4 (*CCR4*); head and neck squamous cell carcinoma (HNSC); biomarker; immune infiltrates

Submitted Jul 16, 2021. Accepted for publication Sep 02, 2021.

doi: 10.21037/atm-21-3936

View this article at: <https://dx.doi.org/10.21037/atm-21-3936>

[^] ORCID: 0000-0002-7607-2516.

Introduction

Head and neck tumors refer to tumors located above the clavicle and below the skull base. About 90% of head and neck malignant tumors are squamous cell carcinoma (1). Head and neck squamous cell carcinoma (HNSC) has a high rate of recurrence and distant metastasis, creating a significant health burden worldwide (2). Early diagnosis and treatment can result in a better prognosis. Common risk factors for HNSC include tobacco, alcohol, environmental risk, and human papillomavirus (HPV) (3). HPV-negative tumors correlate with a worse prognosis (4). No reliable biomarkers have been defined beyond HPV.

Considerable progress has been made in the diagnosis and treatment of HNSC, and surgical treatment, radiotherapy, and chemotherapy can significantly improve the disease control rate and survival rate of patients with HNSC. However, the overall survival rate of patients is still relatively low, with a 5-year survival rate at all stages of about 40–50% (1,5–7). Although immunotherapy has improved the survival rate of some patients in recent years, effective methods to judge the prognosis of patients are still lacking. It is therefore important to find effective prognostic markers.

As a large group of structurally-related cytokines, chemokines play an important role in migration, homing, and tumor microenvironment (8,9). There is still controversy over the link between chemokines and prognosis in different types of cancers because chemokines have both pro- and anticancer properties (10). CC chemokine receptor 4 (*CCR4*) is a receptor of CC chemokine ligand 22 (*CCL22*) and CC chemokine ligand 17 (*CCL17*) and can affect the function of T helper type 2 (Th2) and regulatory T cells (Tregs).

CCR4 is expressed on the surface of T lymphocytes, NK cells, monocytes, macrophages, and eosinophils (11). In T lymphocytes, *CCR4* is mainly expressed on the surface of Th2 cells and CD4+, CD25+ and Treg. It has different functions, so *CCR4* can be divided into: *CCR4*+ Th2 cells and *CCR4*+ Treg cells (12). *CCR4* is expressed on the surface of Treg cells as one of the characteristics of Treg cells. Lechner *et al.* (13) confirmed that compared with normal tissues, Treg cells levels are significantly higher in HNSC and have systemic immunosuppressive activity. When the chemokine TARC/MDC secreted by tumor cells and tumor-infiltrating macrophages binds to the ligand through the receptor *CCR4*, the Treg cells at the tumor site are transported, resulting in a large number of Treg cells aggregation and infiltration in the tumor

microenvironment, making the composition of effector cells and immune regulatory cells in tumor infiltrating lymphocytes (TILs) has changed, which further affects the biological behavior of tumors (12).

Studies have shown that *CCR4* is highly expressed in different tumors and in tumor invasion, and that it plays an essential role in other adverse biological behaviors (14–16). Because *CCR4* recruits cancer-related cells into the tumor microenvironment, patients with high expression of *CCR4* or its chemokines seemed to have a poor prognosis in renal cancer and testicular cancer. In contrast, high expression of *CCR4* or its chemokines improves the prognosis in lung cancer and melanoma patients (15,17,18). There are few reports on the expression of *CCR4* in HNSC tissue and whether *CCR4* is related to tumor prognosis. Although studies have shown that *CCR4* is essential for building a microenvironment that stimulates the anti-tumor immune response to inhibit tumor growth and migration, it has not been evaluated whether *CCR4* can be used as an independent prognostic factor (19). This study analyzed the relationship between *CCR4* and tumor immune infiltration level and clinical tumor prognosis to provide support for further research on HNSC treatment strategies. We present the following article in accordance with the REMARK reporting checklist (available at <https://dx.doi.org/10.21037/atm-21-3936>).

Methods

The Cancer Genome Atlas (TCGA) data acquisition

Level 3 RNA-sequencing data (Fragments Per Kilobase per Million, FPKM) for 33 types of human cancer were download from TCGA through the National Institute of Cancer's Genomic Data Commons (GDC) data portal (<https://portal.gdc.cancer.gov/>). RNA-sequencing data for HNSC and corresponding clinical information were also downloaded from TCGA. RNA sequencing data were transformed to transcripts per million reads (TPM) and normalized into log₂ (TPM +1). HNSC baseline characteristics are detailed in [Table S1](#) in the appendix. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Tumor Immune Estimation Resource (TIMER) database analysis

The TIMER database (<https://cistrome.shinyapps.io/>)

timer/) was used to analyze the correlation between *CCR4* expression level and immune cell infiltration. TIMER was also used to conduct survival analysis for immune cells and *CCR4* in HNSC.

Gene Set Enrichment Analysis (GSEA)

GSEA (<http://software.broadinstitute.org/gsea/index.jsp>) was conducted between high- and low-*CCR4* expression groups to identify *CCR4*-related functional significance in HNSC based on hallmark gene sets (“h.all.v7.0.symbols.gmt”).

Additional bioinformatic and statistical analysis

All analyses were performed with R version 3.6.1. To explore the expression of *CCR4*, Mann-Whitney non-parametric analysis was used to test unpaired differences between groups and Wilcoxon signed-rank test for paired differences. Log rank (Mantel-Cox) test was used for survival analysis. Univariable Cox proportional hazard models were applied to evaluate factors associated with overall survival. To identify independent prognostic factors, all significant variables on univariate Cox regression analysis ($P \leq 0.05$) were subjected to multivariate Cox regression analysis. Wilcoxon test was used for comparisons between 2 groups and the Kruskal-Wallis test was used for multi-group comparisons. Correlation analysis was performed with Spearman’s correlation test. Receiver operating characteristic curves (ROCs) were plotted and areas under the curve (AUC) were calculated using the pROC package in R. Survival analysis was carried out using the R package “Survival”. Univariate Cox and multivariate Cox regression analysis was carried out using the R package “glmnet”. Infiltration levels for different immune cell types were quantified using single-sample gene set enrichment analysis (ssGSEA) with the R package “gsva”. Visualization was performed using the R package “ggplot2” (<http://ggplot2.org>). $P < 0.05$ was considered as significant.

Results

Pan-cancer analysis of *CCR4* expression

The clinical data of 33 different types of tumors were downloaded from TCGA (normal =730, tumor =11,363). As shown in *Figure 1A*, *CCR4* was upregulated in 17 human cancers, including breast invasive carcinoma (BRCA),

cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), colon adenocarcinoma (COAD), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), kidney renal clear cell carcinoma (KIRC), acute myeloid leukemia (LAML), brain lower grade glioma (LGG), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), and thymoma (THYM). *CCR4* was downregulated in adrenocortical carcinoma (ACC), kidney chromophobe (KICH), lung squamous cell carcinoma (LUSC), testicular germ cell tumors (TGCT), and uterine carcinosarcoma (UCS), and there was no significant change in bladder urothelial carcinoma (BLCA), cholangiocarcinoma (CHOL), HNSC, kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), pheochromocytoma and paraganglioma (PCPG), or uterine corpus endometrial carcinoma (UCEC) compared with corresponding normal tissue. Next, the Gene Expression Profiling Interactive Analysis (GEPIA) database was used to analyze the expression profile of *CCR4* in tumor samples and normal tissue. The study found that, compared with normal tissue, the expression of *CCR4* in LUSC is decreased. In short, *CCR4* is upregulated in BRCA, LUSC, STAD, and KIRC/KICH, indicating that *CCR4* may play a key regulatory role in the carcinogenesis of these 4 cancers.

As shown in *Figure 1A*, the expression of *CCR4* did not cause any significant changes in HNSC compared with normal tissue. We then investigated the correlation between expression of *CCR4* and survival in HNSC patients, including overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). With respect to OS, DFS, and PFI, patients with higher expression of *CCR4* had a better prognosis, indicating that *CCR4* could be used as a biomarker to predict prognosis in HNSC patients (*Figure 1*).

Survival analysis of differential expression of *CCR4* and different clinical characteristics

In order to explore the relationship between *CCR4* and various clinical characteristics, we divided the entire cohort into several subgroups to estimate survival curves for high and low expression of *CCR4*. As shown in *Figure 2*, we found that in both early- and late-stage HNSC, patients with high




Figure 1 Expression analysis for CCR4 in 33 cancers and the relationship between CCR4 expression and HNSC survival prognosis. (A) CCR4 expression in 33 human cancers based on TCGA cancer data and normal data. (B) CCR4 expression in TCGA BLCA, BRCA, CHOL, COAD, ESCA, HNSC, KICH, KIRC, KIRP, LIHC, LUAD, LUSC, PAAD, PRAD, READ, STAD, THCA, and UCEC tissue compared with paired normal tissue. (C) OS of CCR4 expression in HNSC. (D) DSS of CCR4 expression in HNSC. (E) PFI of CCR4 expression in HNSC. * $P \leq 0.05$; ** $P \leq 0.01$; *** $P \leq 0.001$; ns, $P > 0.05$. CCR4, CC chemokine receptor 4; HNSC, head and neck squamous cell carcinoma; TGCA, the Cancer Genome Atlas; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; OS, overall survival; DSS, disease specific survival; PFI, progression-free interval.




Figure 2 Survival analysis of different CCR4 subgroups. (A) Survival curve of differential expression of CCR4 in patients with T1/T2 stage HNSC; (B) survival curve of differential expression of CCR4 in patients with T3/T4 stage HNSC; (C) survival curve of differential expression of CCR4 in patients under 60 years of age; (D) survival curve of differential expression of CCR4 in patients over 60 years of age; (E) survival curve of differential expression of CCR4 in patients with G1/G2 grade; (F) survival curve of differential expression of CCR4 in patients with G3/G4 grade. CCR4, CC chemokine receptor 4; HNSC, head and neck squamous cell carcinoma.

expression of *CCR4* had a better prognosis (Figure 2A,2B), and this effect was seen in patients both over and under 60 years old (Figure 2C,2D). Compared to the low *CCR4* expression group, patients in the high *CCR4* expression group with both low and high histologic grades showed a better prognosis (Figure 2E,2F). This result further shows that regardless of tumor stage I/II or III/IV, age over or under 60 years, and histologic grade G 1/2 or 3/4, HNSC patients with high expression of *CCR4* had a better prognosis, once again indicating that *CCR4* could be used as a biomarker to predict prognosis in HNSC patients.

Relationship between *CCR4* expression and *TP53* in HNSC

TP53 plays an important role in HNSC as a suppressor gene. Therefore, we further explored the relationship between *CCR4* expression, prognosis, and *TP53*. The study cohort data included information on the presence of tumors with *TP53* mutations in HNSC. *TP53* mutations were

present in 340 patients (68.8%) and wild-type *TP53* in 154 patients (31.2%). As shown in Figure 3, *CCR4* expression was significantly correlated with the presence of *TP53* mutations. *CCR4* expression of wild-type *TP53* was higher and prognosis better compared to that of mutant *TP53* ($P < 0.05$). In addition, we observed that the differential expression of *TP53* affected the expression level of CD274. High expression of wild-type *TP53* had the highest expression of CD274, and high-expressed wild-type *TP53* had the longest median survival time ($P < 0.05$).

Relationship between *CCR4* expression and clinical characteristics in HNSC

We used Cox regression analysis to perform univariate and multivariate correlation analysis. As shown in Figure 4, tumor grade, pathological Tumor-Node-Metastasis (pTNM) stage, and *CCR4* expression were all significantly correlated with overall survival. Therefore, tumor grade,




Figure 3 Expression of *CCR4* in the mutant and wild-type *TP53* groups and relationship with prognosis. (A) The expression of *CCR4* in the wild-type *TP53* group was significantly higher than that in the mutant group; (B) the prognosis of the wild-type *TP53* group was better than that of the mutant *TP53* group; (C) the expression of *CD274* in differentially expressed wild-type and mutant *TP53* groups; (D) compared to the mutant *TP53* group, high expression of wild-type *TP53* suggested a better prognosis. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; ns, $P > 0.05$. *CCR4*, CC chemokine receptor 4.

pTNM stage, and *CCR4* expression could be considered independent prognostic factors.

The relationship between CCR4 expression and tumor-infiltrating immune cells

In the treatment of malignant tumors, tumor-infiltrating immune cells play a vital role in tumor control and treatment response. Many studies have confirmed that tumor-infiltrating immune cells are closely related to survival and prognosis in various cancers. Therefore, we investigated the relationship between *CCR4* expression and immune infiltration in HNSC. The CIBERSORT analysis tool (<https://cibersort.stanford.edu>) was used to estimate the composition of 24 immune cells and evaluate their different concentrations in the high and low *CCR4* expression groups. *Figure 5* shows the proportion of immune cell subsets in

differentially expressed *CCR4*. The high *CCR4* expression group was rich in activated dendritic cells (aDC), B cells, T cells, cytotoxic cells, DC, eosinophils, immature DC (iDC), macrophages, mast cells, neutrophils, $CD56^{dim}$ natural killer (NK) cells, NK cells, plasmacytoid DC (pDC), T helper (Th) cells, central memory T (TCM) cells, effector memory T (TEM) cells, follicular helper T (TFH) cells, T helper 1 (Th1) cells, Th17 cells, Th2 cells, and Tregs ($P < 0.05$). These immune cells were positively correlated with *CCR4* expression. While the tumor growth delay (TGD) was negatively correlated with *CCR4* expression, the low *CCR4* expression group had a higher TGD ($P < 0.05$).

CCR4 expression is correlated with immune infiltration level in HNSC

Tumor infiltrating lymphocytes independently predict




Figure 4 Association between overall survival and clinical pathological characteristics in HNSC patients using Cox regression model (with pTNM stage, tumor grade, and CCR4 expression as independent prognostic factors). CCR4, CC chemokine receptor 4; HNSC, head and neck squamous cell carcinoma.

the overall survival rate and sentinel lymph node status of cancer patients. This allowed us to use TIMER to evaluate the correlation between *CCR4* expression and the level of immune infiltration in different types of tumors. As shown in *Figure 6*, the expression level of *CCR4* is positively correlated with B cell ($r=0.484$, $P=2.93e-29$), CD4+ T cell ($r=0.683$, $P=4.20e-67$), CD8+ T cell ($r=0.525$, $P=6.67e-35$), macrophage ($r=0.541$, $P=4.39e-38$), neutrophil ($r=0.526$, $P=1.75e-35$), and DC ($r=0.701$, $P=1.82e-72$) immune infiltration level, and B cells, T cells, and *CCR4* are related to the cumulative survival of HNSC over time rate-related factors. The above results indicate that *CCR4* played a specific role in the level of tumor cell immune infiltration in HNSC.

***CCR4* expression is correlated with immune checkpoints in HNSC**

As immune checkpoints have been used in clinical treatment, we plotted the relationship between immune checkpoints and *CCR4* to further clarify the relationship between *CCR4* and immunity, including sialic acid binding Ig-like lectin 15 (SIGLEC15), CD274, programmed

cell death 1 ligand 2 (PDCD1LG2), hepatitis A virus cellular receptor 2 (HAVCR2), cytotoxic T-lymphocyte associated protein 4 (CTLA4), lymphocyte activating 3 (LAG3), programmed cell death 1 (PDCD1), and T cell immunoreceptor with Ig and ITIM domains (TIGIT) (*Figure 7A*). Our results found that the expression of *CCR4* was positively correlated with these 8 immune checkpoints (*Figure 7B-7I*). These results confirmed that the expression of *CCR4* is specifically related to immune infiltrating cells in HNSC, and that *CCR4* played an important role in tumor immune escape.

Gene sets enriched in CCR4 expression phenotype

GSEA results showed that 5 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were enriched in the high *CCR4* expression group, including allograft rejection, inflammatory response, IL-6/JAK/STAT3 signaling, interferon gamma response, and KRAS signaling up (*Figure 8A*). Five KEGG pathways were enriched in the low *CCR4* expression group, including oxidative phosphorylation, MYC targets v1, DNA repair, reactive oxygen species pathway, and P53 pathway (*Figure 8B*).




Figure 5 Infiltrated immune cells in differentially expressed *CCR4* groups. (A) Difference of 24 infiltrated immune cells in *CCR4* between high and low expression groups; (B) correlation between high and low expression of *CCR4* and infiltrated immune cells. * $P \leq 0.05$; *** $P \leq 0.001$; NS: $P > 0.05$. *CCR4*, CC chemokine receptor 4.

These findings indicated that *CCR4* had potential value in the development of HNSC.

The prognostic value of *CCR4* in patients with radiotherapy

We evaluated the prognostic value of *CCR4* in patients receiving radiotherapy (Figure 9). As shown in Figure 9A, we found that patients with high expression of *CCR4* had better OS than patients with low *CCR4* expression. As shown in Figure 9B, patients with high expression of *CCR4* also had better PFS than patients with low *CCR4* expression. After follow-up, we also found that the patients who had received radiotherapy had better OS and PFS during the 5-year follow-up (Figure 9C,9D). These results indicated that *CCR4* was also a good prognostic biomarker in HNSC patients who have received radiotherapy.

Discussion

Cellular immunity plays an important role in antitumor

immunity. T cells, NK cells, and macrophages are the main effector cells of the immune system. Chemokines actively participate in the tumor immune process by affecting the distribution and function of immune cells in the body. Changes in the expression level of chemokines in the tumor microenvironment will inevitably change the number of immune cells infiltrating the tumor tissue.

Chemokines are usually divided into 4 groups consisting of C, CC, CXC, and CX3C, based on conserved cysteines (20,21). Most chemokine receptors recognize more than 1 chemokine. *CCR4*, as the receptor of the CC family, can recognize CCL17 and CCL22. *CCR4* is expressed in T cells and plays multiple roles simultaneously, including regulating biological functions of T cells and Th2 cells (22,23). Previous studies have reported that *CCR4* regulated the traffic of dendritic cells, recirculated T cells from tissue to draining lymph nodes, and migrated T cells to ectopic lymphoid tissue (24,25). *CCR4* has also been found to be expressed in some epithelial cells, such as lung, colon, and bronchial epithelial cells (26,27) and to play an important




Figure 6 Correlation between CCR4 and immune cells in HNSC. (A) The expression of CCR4 had a positive correlation with B cell, CD8+ T cell, CD4+ T cell, macrophage, neutrophil, and dendritic cell infiltration level; (B) cumulative survival was related to B cells, T cells, and CCR4 in HNSC. CCR4, CC chemokine receptor 4; HNSC, head and neck squamous cell carcinoma.




Figure 7 Relationship between the expression of CCR4 and eight immune checkpoints in HNSC. (A) The relationship between CCR4 and immune checkpoints; (B) The expression correlation of CCR4 with TIGIT in HNSC; (C) the expression correlation of CCR4 with PDCD1 in HNSC; (D) the expression correlation of SIGLEC15 with CCR4 in HNSC; (E) the expression correlation of CCR4 with PDCD1LG2 in HNSC; (F) the expression correlation of CCR4 with LAG3 in HNSC; (G) the expression correlation of CCR4 with HAVCR2 in HNSC; (H) the expression correlation of CCR4 with CD274 in HNSC; (I) the expression correlation of CCR4 with CTLA4 in HNSC. *** $P \leq 0.001$. CCR4, CC chemokine receptor 4; HNSC, head and neck squamous cell carcinoma; HAVCR2, hepatitis A virus cellular receptor 2; SIGLEC15, sialic acid binding Ig-like lectin 15; PDCD1LG2, programmed cell death 1 ligand 2; LAG3, lymphocyte activating 3; CTLA4, cytotoxic T-lymphocyte associated protein 4.

role in many malignant tumors, including solid and hematological tumors (28-30).

Recent studies have further confirmed that chemokines are also involved in angiogenesis, embryonic development,

tumor metastasis and other processes (31). Human immune cells such as T lymphocytes, NK cells, monocytes and eosinophils all have CCR4 expressed on the cell surface (32). T lymphocytes play a key role in the body's immune




Figure 8 Enrichment plot from Gene Set Enrichment Analysis (GSEA). (A) GSEA results show that hallmark genes with high CC chemokine receptor 4 (CCR4) expression are differentially enriched; (B) GSEA results show the differential enrichment of hallmark genes with low expression of CCR4. GSEA, Gene Set Enrichment Analysis; CCR4, CC chemokine receptor 4.




Figure 9 The prognostic value of CCR4 in HNSC patients with radiotherapy. (A) Kaplan-Meier survival analysis of PFS and CCR4 expression in HNSC patients with radiotherapy; (B) Kaplan-Meier survival analysis of OS and CCR4 expression in HNSC patients with radiotherapy; (C) ROC analysis of CCR4 on PFS at 2-, 3-, and 5-year follow-up in HNSC patients with radiotherapy; (D) ROC analysis of CCR4 on OS at 2-, 4-, and 5-year follow-up in HNSC patients with radiotherapy. CCR4, CC chemokine receptor 4; HNSC, head and neck squamous cell carcinoma.

response, and the chemokine receptor *CCR4* has mostly focused on it and T cells (33-35). *CCR4* is predominantly expressed on the surface of regulatory T cells and helper Th2 cells, and mediates different types of biological effects in cells. Its related ligands include *CCL17* and *CCL22* (36). Adult peripheral blood data confirm that chemokines The receptor *CCR4* can be detected on the surface of about 20% of effector T cells (37), and the number of Th2 cells is dominant. It has been confirmed in transplantation, inflammation and autoimmune diseases that Th2 cells are induced by *CCR4* to bind to their ligands *CCL17/CCL22* and then aggregate, and the polarization of Th2/Th1 cells is related to the development of their diseases (38).

Thymus and activation-regulated chemokine (TARC/*CCL17*) and human macrophage-derived chemokine (hMDC/*CCL22*) produce different outcomes by binding with *CCR4* (39,40). *CCL17* is expressed widely in more cell types, including both immune and nonimmune cells, compared with *CCL22* which is limited to immune cells (41). *CCL17* and *CCL22* appear to compete to bind with *CCR4*. Treg cells and Th2 cells accumulate and infiltrate in the tumor microenvironment through the combination of *CCL17/CCL22* and *CCR4*.

In some cases, *CCR4* acts as a tumor promoter. *CCR4* can recruit Tregs which can promote the immune escape of cancers (42). Tregs recruited by *CCR4* have even been reported to evoke immunotherapy resistance (43). *CCR4* is also believed to correlate with cancer metastasis. Previous studies have reported that *CCR4* promoted lung metastasis in breast cancer, brain metastasis in melanoma, bone metastasis in lung cancer, and so on (44). However, other studies lean towards the opposite opinion (19,45). Thus, the role of *CCR4* in HNSC needs to be clarified.

In our study, we found the infiltrating level of many types of immune cells were positively related to the expression of *CCR4*, especially CD4+ T cells, CD8+ T cells, and B cells. High levels of CD8+ T cells and B cells predicted a better prognosis in HNSC in our study. Activated CD8+ T lymphocytes are thought to kill cancer cells by exerting antitumor effects and have been reported in many studies to indicate a good prognosis (46,47). Other studies have also verified the good prognostic value of CD20+ B lymphocytes in cancers, and synergistic effects may exist between CD8+ T lymphocytes and B lymphocytes (48,49). This might explain, to some extent, why patients with high expression of *CCR4* had better prognoses in HNSC. Immune regulation is a complex process *in vivo*. Together with the existing evidence, the findings of our study

showed that *CCR4* played multifaceted roles in the immune microenvironment in different tumors. Further, we plotted the relationship between immune checkpoints and *CCR4* to clarify the relationship between *CCR4* and tumor immune escape. These results confirmed that *CCR4* also played an important role in the immune escape mechanism of tumors.

TP53 as a suppressor gene also plays an essential role in HNSC. In our study, we found that patients with a mutation of *TP53* had a worse prognosis, which is consistent with the findings of the available literature. At the same time, we showed that the expression of *CCR4* in wild-type *TP53* significantly outyields that in mutant. In both the mutant *TP53* and wild-type *TP53* groups, high expression of *CCR4* was a marker for a better prognosis.

To further investigate the functions of *CCR4* in HNSC, the transcriptome from TCGA was assessed by GSEA, which found that allograft rejection, inflammatory response, and IL-6 pathways were upregulated in the high *CCR4* expression group. In the low *CCR4* expression group, oxidative phosphorylation, DNA repair, MYC, reactive oxygen species pathway, and p53 pathway were enriched. Oxidative phosphorylation has been reported in many studies to promote tumor growth *in vivo* (50). MYC as an oncogene often regulates differentiation, proliferation, apoptosis, metabolism, and DNA repair of cancers (51). These are all possible mechanisms involved in prognosis.

Although radiotherapy is an important treatment method for HNSC patients, under simple radiotherapy irradiation, tumor cells often develop radiotherapy resistance, which is related to the repair of DNA damage of tumor cells after radiotherapy. After many years evaluating different prognostic markers of HNSC, we have still not found a validated biomarker to predict the response to radiotherapy. Therefore, we evaluated the prognostic value of *CCR4* in HNSC patients receiving radiotherapy. Our results indicated that *CCR4* had a good prognosis in patients with radiotherapy. In short, *CCR4* was a promising prognostic biomarker, but further research is needed to clarify this.

In summary, we suggested that *CCR4* could be used as a prognostic biomarker for HNSC patients. At the same time, *CCR4* was also closely related to tumor immune infiltration, and it is hoped that it will become a new immunotherapy target. However, the specific mechanism of *CCR4* overexpression in the development of HNSC is still unclear and further research is urgently needed.

Our study had several limitations. Different kinds of tumors have specific immune microenvironments and the mechanisms of these are still unclear. *CCR4* may not be the

driving force of a good prognosis in HNSC as we cannot ignore the synergistic effect of different immune cells. Nonetheless, in the unique immune microenvironment of HNSC, we did find that the high expression of *CCR4* correlated with a good prognosis. The second concern relates to the low sample number and missing treatment information, which might have introduced bias into our study; however, our results across different subgroups all proved our conclusion. Further studies with larger cohorts are necessary to confirm the results.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the REMARK reporting checklist. Available at <https://dx.doi.org/10.21037/atm-21-3936>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://dx.doi.org/10.21037/atm-21-3936>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Travassos DC, Fernandes D, Massucato EMS, et al. Squamous cell carcinoma antigen as a prognostic marker and its correlation with clinicopathological features in head and neck squamous cell carcinoma: Systematic review and meta-analysis. *J Oral Pathol Med* 2018;47:3-10.
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71:209-49.
3. Castellsagué X, Alemany L, Quer M, et al. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. *J Natl Cancer Inst* 2016;108:djv403.
4. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med* 2010;363:24-35.
5. Sawant SS, Zingde SM, Vaidya MM. Cytokeratin fragments in the serum: their utility for the management of oral cancer. *Oral Oncol* 2008;44:722-32.
6. Wu XL, Tu Q, Faure G, et al. Diagnostic and Prognostic Value of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: a systematic review and meta-analysis. *Sci Rep* 2016;6:20210.
7. Kulasinghe A, Kenny L, Punyadeera C. Circulating tumour cell PD-L1 test for head and neck cancers. *Oral Oncol* 2017;75:6-7.
8. Röhrle N, Knott MML, Anz D. CCL22 Signaling in the Tumor Environment. *Adv Exp Med Biol* 2020;1231:79-96.
9. Yoshie O, Matsushima K. CCR4 and its ligands: from bench to bedside. *Int Immunol* 2015;27:11-20.
10. Mukherjee D, Zhao J. The Role of chemokine receptor CXCR4 in breast cancer metastasis. *Am J Cancer Res* 2013;3:46-57.
11. Weihrauch MR, Manzke O, Beyer M, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: Potential for a prognostic factor. *Cancer Res* 2005;65:5516-9.
12. Shimauchi T, Kabashima K, Tokura Y. Adult T-cell leukemia/lymphoma cells from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells. *Cancer Sci* 2008;99:98-106.
13. Lechner A, Schloser H, Rothschild SI, et al. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. *Oncotarget* 2017;8:44418-33.
14. Hu TH, Yao Y, Yu S, et al. SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/ β -catenin signaling pathway. *Cancer Lett* 2014;354:417-26.
15. Weide B, Allgaier N, Hector A, et al. Increased CCL17

- serum levels are associated with improved survival in advanced melanoma. *Cancer Immunol Immunother* 2015;64:1075-82.
16. Nakanishi T, Imaizumi K, Hasegawa Y, et al. Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer. *Cancer Immunol Immunother* 2006;55:1320-9.
 17. Li T, Fan J, Wang B, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. *Cancer Res* 2017;77:e108-10.
 18. Summerfield A, McNeilly F, Walker I, et al. Depletion of CD4(+) and CD8(high+) T-cells before the onset of viraemia during classical swine fever. *Vet Immunol Immunopathol* 2001;78:3-19.
 19. Meng L, He X, Hong Q, et al. CCR4, CCR8, and P2RY14 as Prognostic Factors in Head and Neck Squamous Cell Carcinoma Are Involved in the Remodeling of the Tumor Microenvironment. *Front Oncol* 2021;11:618187.
 20. Imai T, Nagira M, Takagi S, et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. *Int Immunol* 1999;11:81-8.
 21. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. *J Exp Med* 1998;187:129-34.
 22. Sozzani S, Allavena P, Vecchi A, et al. The role of chemokines in the regulation of dendritic cell trafficking. *J Leukoc Biol* 1999;66:1-9.
 23. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. *Pharmacol Rev* 2000;52:145-76.
 24. Cowan JE, McCarthy NI, Parnell SM, et al. Differential requirement for CCR4 and CCR7 during the development of innate and adaptive $\alpha\beta$ T cells in the adult thymus. *J Immunol* 2014;193:1204-12.
 25. Mishalian I, Bayuh R, Eruslanov E, et al. Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity. *Int J Cancer* 2014;135:1178-86.
 26. Gniadecki R. CCR4-targeted therapy in cutaneous T-cell lymphoma. *Lancet Oncol* 2018;19:1140-1.
 27. Li JY, Ou ZL, Yu SJ, et al. The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer. *Breast Cancer Res Treat* 2012;131:837-48.
 28. Zhao H, Bo Q, Wang W, et al. CCL17-CCR4 axis promotes metastasis via ERK/MMP13 pathway in bladder cancer. *J Cell Biochem* 2018. [Epub ahead of print]. doi: 10.1002/jcb.27494.
 29. Sohn EJ, Jung DB, Lee H, et al. CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cells. *Cancer Lett* 2018;412:88-98.
 30. Godiska R, Chantry D, Raport CJ, et al. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. *J Exp Med* 1997;185:1595-604.
 31. Tan MC, Goedegebuure PS, Belt BA, et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer [J]. *J Immunol* 2009;182:1746-55.
 32. Wang Y, Zhang Y, Yang X, et al. Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4). *Life Sci* 2006;78:614-21.
 33. Ghadjar P, Rubie C, Aebersold DM, et al. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. *Int J Cancer* 2009;125:741-5.
 34. Hu D, Du C, et al. The expression of chemokine receptors CCR6, CXCR2 and CXCR4 is not organ-specific for distant metastasis in colorectal cancer: a comparative study. *Histopathology* 2013;63:167-73.
 35. Rubie C, Frick VO, et al. CCL20/CCR6 expression profile in pancreatic cancer. *J Transl Med* 2010;8:45.
 36. Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. *Cancer Sci* 2006;97:1139-46.
 37. Ohshima K, Karube K, et al. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis. *Int J Oncol* 2004;25:605-13.
 38. Nicolls MR, Coulombe M, et al. Interferon-gamma is not a universal requirement for islet allograft survival. *Transplantation* 2002;74:472-7.
 39. Santulli-Marotto S, Boakye K, Lacy E, et al. Engagement of two distinct binding domains on CCL17 is required for signaling through CCR4 and establishment of localized inflammatory conditions in the lung. *PLoS One* 2013;8:e81465.
 40. Viney JM, Andrew DP, Phillips RM, et al. Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy. *J Immunol* 2014;192:3419-27.
 41. Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are

- selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. *Cancer Res* 2009;69:2000-9.
42. Marshall LA, Marubayashi S, Jorapur A, et al. Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4. *J Immunother Cancer* 2020;8:e000764.
 43. Nakamura ES, Koizumi K, Kobayashi M, et al. RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. *Clin Exp Metastasis* 2006;23:9-18.
 44. Klein A, Sagi-Assif O, Meshel T, et al. CCR4 is a determinant of melanoma brain metastasis. *Oncotarget* 2017;8:31079-91.
 45. Zhang Z, Liu C, Liang T, et al. Establishment of immune prognostic signature and analysis of prospective molecular mechanisms in childhood osteosarcoma patients. *Medicine (Baltimore)* 2020;99:e23251.
 46. Vihervuori H, Autere TA, Repo H, et al. Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer. *J Cancer Res Clin Oncol* 2019;145:3105-14.
 47. E J, Yan F, Kang Z, et al. CD8+CXCR5+ T cells in tumor-draining lymph nodes are highly activated and predict better prognosis in colorectal cancer. *Hum Immunol* 2018;79:446-52.
 48. Edin S, Kaprio T, Hagström J, et al. The Prognostic Importance of CD20+ B lymphocytes in Colorectal Cancer and the Relation to Other Immune Cell subsets. *Sci Rep* 2019;9:19997.
 49. Sakimura C, Tanaka H, Okuno T, et al. B cells in tertiary lymphoid structures are associated with favorable prognosis in gastric cancer. *J Surg Res* 2017;215:74-82.
 50. Sica V, Bravo-San Pedro JM, Stoll G, et al. Oxidative phosphorylation as a potential therapeutic target for cancer therapy. *Int J Cancer* 2020;146:10-7.
 51. Duffy MJ, O'Grady S, Tang M, et al. MYC as a target for cancer treatment. *Cancer Treat Rev* 2021;94:102154.

(English Language Editor: A. Muijlswijk)

Cite this article as: Zhang Y, Chen K, Li L, Mao W, Shen D, Yao N, Zhang L. CCR4 is a prognostic biomarker and correlated with immune infiltrates in head and neck squamous cell carcinoma. *Ann Transl Med* 2021;9(18):1443. doi: 10.21037/atm-21-3936

Supplementary

Table S1 Characteristics of the Cancer Genome Atlas (TCGA)-head and neck squamous cell carcinoma (HNSC) patients

Characteristic	Overall (n=502)
T stage, n (%)	
T1	33 (6.8)
T2	144 (29.6)
T3	131 (26.9)
T4	179 (36.8)
N stage, n (%)	
N0	239 (49.8)
N1	80 (16.7)
N2	154 (32.1)
N3	7 (1.5)
M stage, n (%)	
M0	472 (99.0)
M1	5 (1.0)
Clinical stage, n (%)	
Stage I	19 (3.9)
Stage II	95 (19.5)
Stage III	102 (20.9)
Stage IV	272 (55.7)
Radiation therapy, n (%)	
No	154 (34.9)
Yes	287 (65.1)
Gender, n (%)	
Female	134 (26.7)
Male	368 (73.3)
Age, n (%)	
≤60	245 (48.9)
>60	256 (51.1)
Histologic grade, n (%)	
G1	62 (12.8)
G2	300 (62.1)
G3	119 (24.6)
G4	2 (0.4)
Smoker, n (%)	
No	111 (22.6)
Yes	381 (77.4)
Alcohol history, n (%)	
No	158 (32.2)
Yes	333 (67.8)